Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Unicycive Therapeutics (UNCY – Research Report) today and set a price ...

H.C. Wainwright raised the firm’s price target on Unicycive Therapeutics (UNCY) to $4 from $2.50 and keeps a Buy rating on the shares ...

LOS ALTOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive ...

The FDA has started a review of Unicycive Therapeutics' drug for hyperphosphataemia in patients with chronic kidney disease ...

Unicycive, which is seeking an FDA green light for oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis, Monday said the agency set a target ...

On Friday, Unicycive Therapeutics Inc (UNCY) stock saw a modest uptick, ending the day at $0.59 which represents a slight increase of $0.02 or 3.51% from the prior close of $0.57. The stock opened at ...

Karnataka: Shilpa Medicare CDMO partner Unicycive Therapeutics, Inc. has announced that the U.S. Food and Drug Administration ...

UNCY Stock Performance and Moving Averages. In recent trading, Unicycive Therapeutics Inc (UNCY) stock price has shown some volatility, fluctuating 6.50% over the last five trades ...

Unicycive has entered into a long term manufacturing contract with Shilpa Medicare for the supply of the product at commercial scale once approved by the USFDA. With Unicycive's NDA now under review, ...

FDA sets PDUFA Action Date of June 28, 2025 ...

Unicycive Therapeutics (UNCY) announced that multiple presentations were delivered at the American Society of Nephrology Kidney Week 2024 that highlighted the extensive development progress for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...